Palo Santo is a Chicago, Illinois-based early-stage venture capital firm founded in 2020 by Daniel Goldberg, Tim Schlidt, and Tony Eisenberg. It is dedicated to investing in breakthrough mental health and neurological therapeutics, spanning differentiated CNS targets, next-generation psychedelic medicines, and cutting-edge research tools that advance translational neuroscience.

The firm has raised over $50M across its funds and has a portfolio of 25+ companies including Gilgamesh Pharmaceuticals, Delix Therapeutics, Beckley Psytech, Tactogen, and Transcend Therapeutics. Palo Santo co-invests frequently with re.Mind Capital and Noetic Fund. It also participated in Alto Neuroscience's IPO.

Palo Santo invests globally but is primarily US and Canada-focused. It is a high-priority specialist fund for founders building evidence-based treatments for depression, PTSD, anxiety, OCD, addiction, neurodegeneration, and related CNS conditions.